The OECD carries out work on health data and indicators to improve international comparisons and economic analyses of health systems.
The OECD Health Division is releasing a new series to highlight its work on health policies and data. A new graph will be available each month.
Many European countries saw further reductions in health spending in 2013, according to OECD Health Statistics 2015. Health spending continued to shrink in Greece, Italy and Portugal in 2013. Most countries in the European Union reported real per capita health spending below the levels of 2009. Outside of Europe, health spending has been growing at around 2.5% per year since 2010.
Health workers are crucial for ensuring access to high quality care for the whole population. The OECD advises countries on how to meet future demand for health professionals and how to manage the supply of health workers, by reviewing policies related to education and training, continuous professional development, geographic distribution and immigration.
The objective of the HCQI Project is to develop a set of indicators based on comparable data and which can be used to raise questions for further investigation on quality differences across countries.
The OECD Development Assistance Committee (DAC) collects aid flows at activity level based on a standard methodology and agreed definitions. Aid to Health is covered by two main sectors; 1.Aid to Health - General and Basic Health, and, 2. Population Policies/Programmes and Reproductive Health - includes HIV/AIDS.
OECD Health Statistics 2015 is the most comprehensive source of comparable statistics on health and health systems across OECD countries.
English, Excel, 3,894kb
Download this selection of key indicators from OECD Health Statistics 2015, in Excel. Final 2015 version, updated 12 November 2015.
Download data on health expenditure, health care resources, health care activities, mortality, and risk factors. Latest data in Excel format from the database OECD Health Statistics 2014, November 2014 edition.
Statistics on biotechnology firms, biotechnology R&D (including public sector expenditures), biotech applications and patents.